RE:RE:BIOV PapilocareEarlier this year BIO entered a partnership with Procare, a pharmaco in Spain, to codevelop and market BIOV's ovarianc cancer vaccine. The deal included BIOV having right of refusal to market Papilocare in the US. That produce is approved and marketed already in Europe, waiting to hears from FDA in the US. Here is the link to the press release
https://www.prnewswire.com/news-releases/biovaxys-and-procare-health-announce-broad-co-development-joint-commercialization-and-marketing-collaboration-for-cancer-and-viral-vaccines-301225171.html